Human health was once viewed through a purely genomic lens, yet emerging research into the gut-organ axis reveals that our physiology is managed by a “meta-organismal” relay. In this biochemical hand-off, dietary precursors are processed by the enteric microbial ecosystem into volatile intermediates, which are subsequently modified by host organs to produce systemic effects.At the center of this interface is trimethylamine N-oxide (TMAO). Historically known as an obscure marine osmolyte used by deep-sea fish to maintain fluid balance, TMAO has transitioned into a primary target for cardiovascular risk stratification. It is now recognized as a potent predictor of Major Adverse Cardio and Cerebrovascular Events (MACCE), often providing prognostic power that exceeds traditional lipid panels. The question for modern medicine has become: how does a single molecule, synthesized at the intersection of diet and the microbiome, dictate the trajectory of systemic disease?<\/p>\n
La s\u00edntesis de TMAO es un proceso preciso de m\u00faltiples pasos que requiere una contribuci\u00f3n obligatoria de las bacterias intestinales. Sin enzimas microbianas espec\u00edficas, los precursores que comemos nunca se convertir\u00edan en esta mol\u00e9cula proaterog\u00e9nica.<\/p>\n
Los mariscos son naturalmente ricos en \u00d3xido de Trimetilamina (TMAO) preformado. En consecuencia, una sola porci\u00f3n de pescado puede elevar los niveles plasm\u00e1ticos de TMAO significativamente m\u00e1s que una porci\u00f3n de carne roja. Sin embargo, los datos epidemiol\u00f3gicos confirman consistentemente que el consumo de pescado es cardioprotector. Esta aparente contradicci\u00f3n se resuelve mediante tres factores distintos:<\/p>\n
TMAO does not directly trigger coagulation; rather, it functions as a pro-thrombotic sensitizer. It acts as a biochemical\u00a0 re\u00f3stato<\/strong> , “dialing up” the reactivity of platelets to primary agonists like thrombin or collagen.The molecular mechanism involves the modulation of intracellular calcium ( $Ca^{2+}$ ) signaling. TMAO facilitates the rapid release of\u00a0 $Ca^{2+}$\u00a0 from internal stores\u2014specifically the\u00a0 sistema tubular denso<\/strong> \u2014within the platelets. This heightened calcium flux makes platelets “twitchier” and more prone to aggregation under high-shear conditions, increasing the risk of myocardial infarction and stroke. The causal nature of this link was demonstrated by the removal of the microbial\u00a0 cortarC<\/em>\u00a0 gene in experimental models; eliminating the gut’s ability to produce the TMA precursor completely abolished this heightened thrombotic potential.<\/p>\n While TMAO is a staple of cardiovascular research, it is increasingly viewed as a global marker of health, with profound implications for the “Microbiota-Gut-Brain Axis” and renal longevity.<\/p>\n Traditional approaches to microbiome modulation involved broad-spectrum antibiotics, which act as a “scorched earth” strategy. The future of TMAO management lies in “non-lethal” small-molecule inhibitors that target the enzyme (TMA lyase) rather than the bacteria themselves, avoiding the risk of antibiotic resistance.| Inhibitor Class | Key Compound | Mechanism of Action | Potency & Status || —— | —— | —— | —— || Inhibidores competitivos<\/strong> | DMB (found in olive oil) | Mimics choline to competitively block CutC\/D | Preclinical; naturally occurring || Sustratos suicidas<\/strong> | IMC \/ FMC | Irreversiblemente<\/strong>\u00a0 se une a la enzima CutC\/D y la desactiva potencia nanomolar<\/strong>\u00a0 ( $IC_{50}$ ); alto perfil de seguridad |<\/p>\n Compuestos como la yodometilcolina (IMC) han demostrado la capacidad de reducir el TMAO sist\u00e9mico y disminuir el riesgo tromb\u00f3tico sin aumentar el tiempo de sangrado, lo que representa un cambio de paradigma en la farmacolog\u00eda de precisi\u00f3n del microbioma.<\/p>\n TMAO serves as a high-fidelity mirror reflecting the interface between our dietary inputs and our internal microbial ecosystem. It is no longer just a biomarker; it is a bioactive participant in the pathogenesis of cardiovascular, renal, and neurodegenerative diseases.As we transition toward “stratified nutrition,” an individual\u2019s gut profile\u2014specifically the abundance of microbial\u00a0 cortarC<\/em>\u00a0 genes and the activity of hepatic FMO3\u2014will likely dictate personalized dietary interventions. By identifying “high TMA-producers” early, we can move beyond generalized advice toward targeted microbiome management. The state of your heart is, quite literally, a reflection of the invisible metabolic relay occurring in your gut. What is your internal factory producing?<\/p>\n The emergence of trimethylamine N-oxide (TMAO) as a central player in cardiometabolic medicine represents a major shift in how researchers understand the interaction between diet, the gut microbiome, and human health. TMAO, a small organic compound with the molecular formula C5H11NO2<\/strong>, is a water-soluble amine N-oxide that has moved from being a relatively obscure osmolyte in marine biology to a widely studied candidate biomarker and potential mediator of cardiovascular risk. The synthesis of TMAO is a multi-step process that bridges the external environment (diet), the enteric microbial ecosystem (gut microbiota), and the host’s internal physiology (liver and kidneys). This report provides an exhaustive, expert-level deep dive into the TMAO axis, analyzing its biochemical architecture, the molecular mechanisms through which it may promote disease, the clinical evidence supporting its prognostic value, and the contemporary controversies regarding its status as a causal agent versus a surrogate biomarker of systemic dysbiosis and cardiometabolic risk.<\/p>\n La producci\u00f3n de TMAO no es un resultado directo del metabolismo celular humano, sino m\u00e1s bien un proceso metaorganismal que requiere una contribuci\u00f3n obligatoria de la microbiota intestinal. Esta v\u00eda se inicia cuando se consumen precursores diet\u00e9ticos que posteriormente se transforman en intermediarios vol\u00e1tiles que el hu\u00e9sped luego modifica.<\/p>\n Las materias primas principales para la s\u00edntesis de TMAO son los compuestos de amonio cuaternario que se encuentran en abundancia en muchos alimentos de origen animal, aunque algunos alimentos de origen vegetal tambi\u00e9n contribuyen a trav\u00e9s de su contenido de beta\u00edna y colina. Los precursores m\u00e1s destacados incluyen la colina (que a menudo se encuentra en forma de fosfatidilcolina o lecitina), la L-carnitina, la beta\u00edna, g-butirobeta\u00edna<\/strong>, y crotonobeta\u00edna.<\/p>\n The transformation of these nutrients begins in the intestinal lumen. Dietary choline and carnitine are metabolized by specific microbial enzymes. The cleavage of the carbon-nitrogen bond in choline is catalyzed by the glycyl radical enzyme choline trimethylamine-lyase, encoded by the cortarC<\/strong> gene, and its activating protein, encoded by cortar D<\/strong>. Esta reacci\u00f3n libera trimetilamina (TMA) como subproducto vol\u00e1til. De manera similar, la L-carnitina puede metabolizarse a trav\u00e9s de una v\u00eda distinta que involucra el sistema de la carnitina monooxigenasa (codificado por cntA<\/strong> y cntB<\/strong>), lo que tambi\u00e9n resulta en la producci\u00f3n de TMA.<\/p>\n Investigaciones recientes han a\u00f1adido matices significativos a la ruta de la carnitina al identificar \u03b3-butirobeta\u00edna (\u03b3BB)<\/strong> as a major intermediary metabolite. Following the ingestion of L-carnitine, \u03b3BB is produced at a rate approximately 1,000-fold higher than the direct formation of TMA in the proximal gut. This \u03b3BB is then converted into TMA by a specialized subset of the microbiota in a secondary step. The presence of these intermediates suggests that the gut’s metabolic capacity for TMAO precursors is not a single-step reaction but a complex relay between different microbial taxa.<\/p>\n Una vez que la TMA se produce en el intestino, es absorbida a trav\u00e9s del epitelio intestinal y transportada a trav\u00e9s de la vena porta hasta el h\u00edgado. La TMA es un compuesto altamente vol\u00e1til y maloliente; en los seres humanos, su conversi\u00f3n r\u00e1pida en TMAO, que carece de olor, es un paso cr\u00edtico de desintoxicaci\u00f3n. Esta oxidaci\u00f3n es catalizada por la familia de enzimas monooxigenasas que contienen flavina (FMO), espec\u00edficamente la FMO3<\/strong> isoforma, que es responsable de la gran mayor\u00eda de la conversi\u00f3n de TMA a TMAO en el h\u00edgado.<\/p>\n La actividad de la FMO3 es un determinante importante de los niveles circulantes de TMAO. Los polimorfismos gen\u00e9ticos en la FMO3<\/strong> gene can lead to reduced enzymatic activity, resulting in the accumulation of TMA and the condition known as trimethylaminuria, or fish-odor syndrome, where TMA is excreted in sweat, breath, and urine. Conversely, increased FMO3 activity – which is influenced by host factors including bile-acid signaling and FXR-related pathways – can raise systemic TMAO concentrations even in the absence of extreme precursor intake. After its formation in the liver, TMAO enters the systemic circulation and is primarily eliminated by the kidneys through glomerular filtration.<\/p>\n The pathogenicity of TMAO has been linked to a diverse range of mechanisms that influence cellular stress, inflammatory signaling, thrombosis, and lipid homeostasis. Experimental models have moved beyond simple correlation to identify intracellular targets that TMAO may modulate at physiologic or pathophysiologic concentrations. Still, many of these mechanisms remain best established in preclinical systems rather than definitive human intervention studies.<\/p>\n One of the hallmark pro-atherogenic mechanisms attributed to TMAO is disruption of cholesterol homeostasis. Under normal conditions, the body maintains balance through reverse cholesterol transport (RCT), where excess cholesterol from peripheral macrophages is transported back to the liver for excretion in bile. TMAO has been shown in animal models to impair this process.<\/p>\n En modelos murinos, la suplementaci\u00f3n diet\u00e9tica con TMAO provoca una reducci\u00f3n de aproximadamente 35% en la capacidad de la RCT. Este deterioro parece producirse a trav\u00e9s de varias v\u00edas paralelas:<\/p>\n TMAO acts as a stimulus for vascular inflammation and endothelial dysfunction, both of which are important early steps in atherogenesis. One frequently discussed pathway in this context is activation of the inflamasoma NLRP3<\/strong>.<\/p>\n The proposed mechanism involves mitochondrial dysfunction and the accumulation of mitochondrial reactive oxygen species (mtROS). TMAO has been reported to suppress expression of the mitochondrial deacetylase SIRT3<\/strong>, lo que lleva a la hiperacetilaci\u00f3n y a una actividad reducida de super\u00f3xido dismutasa 2 (SOD2)<\/strong>. This loss of antioxidant buffering may promote an oxidative burst that activates prote\u00edna que interact\u00faa con la tioredoxina (TXNIP)<\/strong>, which in turn triggers assembly of the NLRP3 inflammasome. Inflammasome activation then promotes cleavage of pro-caspase-1 and release of the pro-inflammatory cytokines IL-1\u03b2<\/strong> y IL-18<\/strong>.<\/p>\n Beyond inflammation, TMAO may also interfere with endothelial self-repair. In cell-based studies, it impairs the proliferation and migration of human umbilical vein endothelial cells (HUVECs) and can activate protein kinase C (PKC), further stabilizing a pro-inflammatory endothelial phenotype.<\/p>\n El TMAO se describe ampliamente como un cometabolito protromb\u00f3tico. No funciona como un agonista primario como la trombina o el col\u00e1geno, sino que parece sensibilizar a las plaquetas a estos est\u00edmulos. La base molecular de este efecto radica en la modulaci\u00f3n del calcio intracelular (Ca2+<\/strong>) se\u00f1alizaci\u00f3n. El TMAO facilita la liberaci\u00f3n de Ca2+<\/strong> de los dep\u00f3sitos plaquetarios internos, lo que genera una mayor agregaci\u00f3n y una formaci\u00f3n de trombos m\u00e1s r\u00e1pida en condiciones de alto cizallamiento. Es importante destacar que la eliminaci\u00f3n de la capacidad microbiana de generar TMA en sistemas experimentales elimina este fenotipo tromb\u00f3tico elevado, lo que respalda el concepto de que el microbioma intestinal puede funcionar como un re\u00f3stato para el riesgo de coagulaci\u00f3n sist\u00e9mica.<\/p>\n Since the initial report linking TMAO to cardiovascular disease in 2011, multiple prospective cohort studies and meta-analyses have evaluated TMAO as an independent predictor of major adverse cardiovascular and cerebrovascular events (MACCE or MACE).<\/p>\n Large-scale meta-analyses involving tens of thousands of participants have provided quantitative evidence for a link between higher plasma TMAO and adverse outcomes. One commonly cited meta-analysis of 14 studies (15,662 participants) found that high plasma TMAO levels were associated with a hazard ratio (HR) of 1.91<\/strong> for all-cause mortality compared with lower levels.<\/p>\n Dose-response analyses have suggested that risk rises incrementally with higher TMAO concentrations. In one meta-analysis, every 10 \u00b5mol\/L<\/strong> el aumento de la TMAO en plasma se asoci\u00f3 con aproximadamente 7.6%<\/strong> higher relative risk of all-cause mortality. These associations often remain statistically significant after adjustment for age, sex, BMI, blood pressure, LDL cholesterol, and smoking status, suggesting that TMAO may capture prognostic information not fully reflected in traditional risk factors alone.<\/p>\n In patients with heart failure (HF), TMAO levels appear to function as both a marker of disease severity and a possible contributor to progression. HF patients often exhibit higher TMAO levels than healthy controls, with levels correlating with BNP and NYHA functional class. Mechanistically, TMAO has been linked to adverse remodeling through several pathways:<\/p>\n La asociaci\u00f3n con el riesgo de insuficiencia card\u00edaca tambi\u00e9n se ha examinado en diversas cohortes comunitarias como la Estudio de Salud Cardiovascular (CHS)<\/strong> y el Estudio Multi\u00e9tnico de la Aterosclerosis (MESA)<\/strong>. En estas cohortes, las concentraciones m\u00e1s altas de TMAO (HR 1,15) y su precursor colina (HR 1,44) se asociaron de forma independiente con la insuficiencia cardiaca incidente, y algunos an\u00e1lisis sugieren asociaciones m\u00e1s fuertes en las poblaciones negra e hispana\/latina.<\/p>\n The relationship between TMAO and chronic kidney disease (CKD) is complex and bidirectional. Because TMAO is cleared by the kidneys, its concentration rises as renal function declines. In patients with end-stage renal disease (ESRD), TMAO levels can exceed 90 \u00b5mol\/L<\/strong>, en comparaci\u00f3n con aproximadamente 3 \u00b5mol\/L<\/strong> en controles sanos.<\/p>\n Sin embargo, el TMAO no es meramente un marcador pasivo de da\u00f1o renal. El trabajo experimental sugiere que puede actuar como una toxina ur\u00e9mica que promueve la fibrosis tubulointersticial renal y la esclerosis glomerular. Esto crea un c\u00edrculo vicioso en el que el da\u00f1o renal conduce a un mayor TMAO, y un mayor TMAO puede empeorar a\u00fan m\u00e1s la lesi\u00f3n renal. El trasplante renal exitoso produce una ca\u00edda marcada en el TMAO plasm\u00e1tico, lo que refuerza que el aclaramiento renal es un determinante primario de los niveles sist\u00e9micos en esta poblaci\u00f3n.<\/p>\n El r\u00e1pido ascenso del TMAO como factor de riesgo cardiovascular ha generado un escrutinio cient\u00edfico sustancial, en particular en torno a si es un impulsor causal de la enfermedad o un marcador de una dieta proaterog\u00e9nica, de un clearance renal alterado o de un desequilibrio m\u00e1s amplio del microbioma.<\/p>\n The best-known controversy is the fish paradox. Fish and seafood are naturally rich in pre-formed TMAO, which they use as an osmoprotectant. Consuming fish can lead to immediate and substantial increases in plasma TMAO – often larger than those observed after red-meat feeding. Yet fish intake is consistently associated with cardioprotective dietary patterns and, in many epidemiologic datasets, lower cardiovascular risk.<\/p>\n Se han propuesto varias explicaciones:<\/p>\n To address causality, investigators have used Mendelian randomization (MR), which relies on genetic variants as instrumental variables to estimate the effect of an exposure such as TMAO on outcomes such as coronary artery disease or stroke.<\/p>\n The MR literature is mixed. Some studies have not supported a direct causal relationship between genetically predicted higher TMAO and coronary artery disease or stroke. This has strengthened the argument that elevated TMAO may sometimes reflect reverse causality, especially when CKD, diabetes, or other chronic disorders elevate TMAO secondarily. However, other MR analyses have suggested possible causal relationships with systolic blood pressure and type 2 diabetes risk. These conflicting results imply that, if TMAO is causal, its effects may be pathway-specific, population-specific, or modified by renal function, diet, and host genetics.<\/p>\n A major limitation in TMAO research is confounding by renal function. Because TMAO depends heavily on glomerular filtration, estimated glomerular filtration rate (eGFR) can materially influence any observed association between TMAO and cardiovascular outcomes. Some studies have found that after adjustment for renal markers, the predictive strength of TMAO is attenuated. Diet quality is another major confounder; higher TMAO often travels with Western-style dietary patterns that are independently linked to cardiovascular risk.<\/p>\n Dado que la producci\u00f3n de TMAO es fundamentalmente una interacci\u00f3n entre la dieta y el microbioma, los cambios en el estilo de vida siguen siendo una estrategia pr\u00e1ctica de primera l\u00ednea para controlar los niveles elevados.<\/p>\n Los patrones diet\u00e9ticos moldean fuertemente la capacidad metab\u00f3lica de la microbiota intestinal.<\/p>\n M\u00e1s all\u00e1 de la dieta, la modulaci\u00f3n directa de la microbiota intestinal es un \u00e1rea activa de investigaci\u00f3n.<\/p>\n La estrategia farmacol\u00f3gica m\u00e1s activa para reducir el TMAO se ha centrado en inhibir las enzimas microbianas que producen TMA, idealmente con compuestos no letales y de acci\u00f3n restringida al intestino.<\/p>\n La v\u00eda terap\u00e9utica m\u00e1s prometedora es la inhibici\u00f3n de las liasas de TMA microbianas, especialmente la CutC\/D<\/strong> A diferencia de los antibi\u00f3ticos, estos agentes est\u00e1n dise\u00f1ados para bloquear la actividad enzim\u00e1tica sin matar a las bacterias, lo que reduce la presi\u00f3n selectiva para la resistencia.<\/p>\n Inhibiendo hep\u00e1tica FMO3<\/strong> es otra v\u00eda te\u00f3rica para reducir el TMAO, pero el enfoque es dif\u00edcil. La FMO3 participa en el metabolismo de muchos xenobi\u00f3ticos, y una inhibici\u00f3n fuerte conlleva el riesgo de toxicidad fuera del blanco, as\u00ed como de trimetilaminuria, lo que probablemente ser\u00eda mal tolerado en la pr\u00e1ctica cl\u00ednica rutinaria.<\/p>\n El alcance de la investigaci\u00f3n sobre el TMAO se est\u00e1 expandiendo m\u00e1s all\u00e1 de la enfermedad cardiometab\u00f3lica hacia la neurodegeneraci\u00f3n y los enfoques de biolog\u00eda de sistemas para la medicina de precisi\u00f3n.<\/p>\n Emerging studies suggest that TMAO may participate in the pathogenesis of neurodegenerative disease, including Alzheimer’s disease and Parkinson’s disease. TMAO has been detected in cerebrospinal fluid, and experimental work suggests it can influence blood-brain barrier biology and neuroinflammatory signaling.<\/p>\n En el cerebro, los mecanismos propuestos incluyen:<\/p>\n The integration of metabolomics, proteomics, metagenomics, and clinical phenotyping is producing a more complete view of the TMAO axis. Large biobank analyses using machine learning suggest that adding multi-omics features may improve disease prediction beyond traditional clinical markers alone. Precision nutrition is a particularly important future application. By characterizing an individual’s gut microbial TMA-producing capacity – for example, cortarC<\/strong> abundance – along with host genetic features such as FMO3<\/strong> variantes, los m\u00e9dicos podr\u00edan eventualmente adaptar las recomendaciones diet\u00e9ticas con mayor precisi\u00f3n.<\/p>\n A pesar de m\u00e1s de una d\u00e9cada de estudio intensivo, es necesario cerrar varias brechas antes de que la medici\u00f3n de TMAO o su reducci\u00f3n dirigida se conviertan en pr\u00e1ctica cl\u00ednica est\u00e1ndar.<\/p>\n Vac\u00edos y necesidades de investigaci\u00f3n<\/strong><\/p>\n La evidencia actual respalda al TMAO como un marcador altamente informativo de la interfaz dieta-microbioma-hospedador y un contribuyente mecan\u00edstico plausible a la enfermedad cardiometab\u00f3lica en al menos algunos contextos. Su asociaci\u00f3n consistente con la mortalidad y los eventos cardiovasculares, junto con mecanismos biol\u00f3gicamente plausibles en estudios precl\u00ednicos, lo convierte en un candidato atractivo para la estratificaci\u00f3n del riesgo y la futura focalizaci\u00f3n terap\u00e9utica.<\/p>\n Al mismo tiempo, el debate sobre la causalidad absoluta sigue sin resolverse. La funci\u00f3n renal, el patr\u00f3n diet\u00e9tico, la gen\u00e9tica del hu\u00e9sped y la composici\u00f3n del microbioma complican la interpretaci\u00f3n. Por ahora, la postura cl\u00ednica m\u00e1s defendible es que el TMAO es un biomarcador pron\u00f3stico y de investigaci\u00f3n \u00fatil con relevancia mecanicista emergente, pero a\u00fan no es un blanco terap\u00e9utico independiente universalmente aceptado. En pacientes de mayor riesgo, un TMAO elevado a\u00fan puede identificar una oportunidad para una asesor\u00eda diet\u00e9tica m\u00e1s firme, una vigilancia renal y cardiometab\u00f3lica m\u00e1s estrecha y, eventualmente, intervenciones de precisi\u00f3n dirigidas al microbioma.<\/p>\nM\u00e1s all\u00e1 del coraz\u00f3n: La conexi\u00f3n entre el cerebro y los ri\u00f1ones<\/h3>\n
\n
“Drugging the Microbiome” Without Killing It<\/h3>\n
Conclusi\u00f3n: Hacia la prevenci\u00f3n personalizada<\/h3>\n
\nAn\u00e1lisis profundo de la investigaci\u00f3n sobre el TMAO<\/h2>\n
El meta-eje meta-organismal del \u00f3xido de trimetilamina N: Un an\u00e1lisis exhaustivo de las v\u00edas bioqu\u00edmicas, la patogenia cardiometab\u00f3lica y las implicaciones cl\u00ednicas<\/strong><\/h3>\n
El panorama bioqu\u00edmico: El eje intestino-h\u00edgado-ri\u00f1\u00f3n<\/h3>\n
Precursores diet\u00e9ticos y la puerta microbiana<\/h4>\n
\n\n
\n Precursor dietario<\/strong><\/td>\n Principales fuentes de alimentos<\/strong><\/td>\n Intermediario metab\u00f3lico<\/strong><\/td>\n Producto Sist\u00e9mico Final<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Colina \/ Fosfatidilcolina<\/td>\n Yemas de huevo, h\u00edgado, l\u00e1cteos, soya<\/td>\n Trimetilamina (TMA)<\/td>\n \u00d3xido de trimetilamina (TMAO)<\/td>\n<\/tr>\n \n L-Carnitina<\/td>\n Carne roja (res, cordero), suplementos<\/td>\n \u03b3-Butyrobetaine (\u03b3BB) \/ TMA<\/td>\n \u00d3xido de trimetilamina (TMAO)<\/td>\n<\/tr>\n \n \u03b3-Butirobeta\u00edna<\/td>\n Preformado en algunas carnes rojas; intermediario microbiano<\/td>\n Trimetilamina (TMA)<\/td>\n \u00d3xido de trimetilamina (TMAO)<\/td>\n<\/tr>\n \n Beta\u00edna<\/td>\n Remolacha, espinaca, granos enteros<\/td>\n Trimetilamina (TMA)<\/td>\n \u00d3xido de trimetilamina (TMAO)<\/td>\n<\/tr>\n \n Crotonobeta\u00edna<\/td>\n subproducto del metabolismo de la carnitina<\/td>\n Trimetilamina (TMA)<\/td>\n \u00d3xido de trimetilamina (TMAO)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Conversi\u00f3n hep\u00e1tica y el papel de la FMO3<\/h4>\n
Mecanismos moleculares de acci\u00f3n: c\u00f3mo el TMAO puede impulsar enfermedades<\/h3>\n
Metabolismo del colesterol y transporte inverso del colesterol<\/h4>\n
\n
Disfunci\u00f3n endotelial y el inflamasoma NLRP3<\/h4>\n
\n\n
\n V\u00eda de se\u00f1alizaci\u00f3n<\/strong><\/td>\n Efecto celular de la TMAO<\/strong><\/td>\n Patolog\u00eda resultante<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n NLRP3 \/ TXNIP<\/td>\n Activaci\u00f3n del inflamasoma y liberaci\u00f3n de citocinas (IL-1\u03b2, IL-18)<\/td>\n inflamaci\u00f3n endotelial, lesi\u00f3n vascular<\/td>\n<\/tr>\n \n NF-\u03baB<\/td>\n Increased expression of VCAM-1 and ICAM-1<\/td>\n Enhanced leukocyte adhesion and migration<\/td>\n<\/tr>\n \n MAPK \/ ERK<\/td>\n Fosforilaci\u00f3n de los nodos de se\u00f1alizaci\u00f3n inflamatoria relacionados con I\u03baB<\/td>\n transcripci\u00f3n de genes proinflamatorios<\/td>\n<\/tr>\n \n VENTAJA (UPR)<\/td>\n Activaci\u00f3n de la se\u00f1alizaci\u00f3n de estr\u00e9s del ret\u00edculo endopl\u00e1smico<\/td>\n Inducci\u00f3n de FoxO1 y disfunci\u00f3n metab\u00f3lica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Hiperreactividad plaquetaria y potencial tromb\u00f3tico<\/h4>\n
Evidencia cl\u00ednica: El TMAO como un marcador pron\u00f3stico global<\/strong><\/h3>\n
Enfermedad cardiovascular y mortalidad por todas las causas<\/h4>\n
\n\n
\n Resultado cl\u00ednico<\/strong><\/td>\n Sujetos \/ Cohortes<\/strong><\/td>\n Estimaci\u00f3n estad\u00edstica (HR\/RR)<\/strong><\/td>\n Confidence Interval (95%)<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Mortalidad por todas las causas<\/td>\n 15,662 sujetos<\/td>\n HR: 1.91<\/td>\n 1.40-2.61<\/td>\n<\/tr>\n \n MACCE \/ MACE<\/td>\n 13,944 sujetos<\/td>\n FC: 1.67<\/td>\n 1.33-2.11<\/td>\n<\/tr>\n \n Eventos cardiovasculares<\/td>\n 10,245 sujetos<\/td>\n HR: 1.23<\/td>\n 1.07-1.42<\/td>\n<\/tr>\n \n Mortalidad (a largo plazo)<\/td>\n 218 sujetos (desnutridos)<\/td>\n HR: 2.01<\/td>\n 1.23-3.31<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Insuficiencia card\u00edaca y remodelaci\u00f3n card\u00edaca<\/h3>\n
\n
Enfermedad renal cr\u00f3nica y el dilema renal<\/strong><\/h4>\n
Controversias y evaluaci\u00f3n cr\u00edtica: Causalidad frente a asociaci\u00f3n<\/h3>\n
La paradoja del pez<\/h4>\n
\n
Aleatorizaci\u00f3n Mendeliana y Perspectivas Gen\u00e9ticas<\/h4>\n
Confusi\u00f3n por funci\u00f3n renal y dieta<\/h4>\n
Influencias de la dieta y el estilo de vida en la v\u00eda de la TMAO<\/h3>\n
Modulaci\u00f3n nutricional<\/h4>\n
\n
Estrategias dirigidas al microbioma<\/h4>\n
\n
Estrategias terap\u00e9uticas: Inhibici\u00f3n farmacol\u00f3gica<\/h3>\n
Inhibidores de la TMA liasa<\/h4>\n
\n
\n\n
\n Clase de inhibidor<\/strong><\/td>\n Compuesto clave<\/strong><\/td>\n Mecanismo de acci\u00f3n<\/strong><\/td>\n Estado cl\u00ednico \/ de investigaci\u00f3n<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Inhibidor competitivo<\/td>\n DMB<\/td>\n An\u00e1logo de la colina; bloquea CutC\/D<\/td>\n Precl\u00ednico<\/td>\n<\/tr>\n \n Sustrato suicida<\/td>\n IMC \/ FMC<\/td>\n Inhibe de forma irreversible CutC\/D<\/td>\n Precl\u00ednico<\/td>\n<\/tr>\n \n Inhibidor hep\u00e1tico<\/td>\n Inhibidores de FMO3<\/td>\n Bloquea la oxidaci\u00f3n de TMA por el hu\u00e9sped<\/td>\n Limitado por toxicidad \/ riesgo de trimetilaminuria<\/td>\n<\/tr>\n \n Modulador indirecto<\/td>\n Canagliflozina<\/td>\n Puede alterar la se\u00f1alizaci\u00f3n metab\u00f3lica entre el intestino y el hu\u00e9sped<\/td>\n Cl\u00ednicamente aprobado, pero no como una terapia espec\u00edfica para el TMAO<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Inhibici\u00f3n de enzimas del hu\u00e9sped<\/h4>\n
Fronteras emergentes: Neurodegeneraci\u00f3n y multi\u00f3mica<\/h3>\n
TMAO y el eje microbiota-intestino-cerebro<\/h4>\n
\n
Multi\u00f3mica y medicina de precisi\u00f3n<\/h4>\n
Evaluaci\u00f3n cr\u00edtica y direcciones futuras<\/h3>\n
\n
Conclusi\u00f3n: \u00bfDebe el TMAO ser un blanco cl\u00ednico?<\/h3>\n
Puntos clave para la pr\u00e1ctica cl\u00ednica<\/h3>\n
\n
Reasignaci\u00f3n de citas evaluadas por pares<\/h3>\n
\n